-
Mycobacterium Tuberculosis(Sputum/Tongue swab sample)
Tuberculosis (TB), caused by Mycobacterium tuberculosis, primarily affects the lungs, with around 10 million new cases annually as of July 2024. Traditional testing methods are often impractical for rapid diagnosis. Our Mycobacterium Tuberculosis Nucleic Acid Test Card offers a user-friendly solution for detecting MTBC DNA in sputum or tongue swab samples, enabling timely diagnosis and management.¥ 0.00More >
-
SARS-CoV-2/FIu A/Flu B
With the rise of respiratory illnesses like COVID-19, Flu A, and Flu B, efficient and accurate testing is vital. As of July 2024, SARS-CoV-2 has caused over 760 million cases worldwide, and seasonal flu affects millions each year. Quick, precise diagnosis is key to effective management. Traditional methods can be cumbersome for rapid, frequent testing.
This kit provides a streamlined solution for in vitro detection of SARS-CoV-2, Influenza A, and Influenza B RNA in nasal swab samples.¥ 0.00More >
-
HPV 16/18/45
HPV types 16, 18, and 45 are linked to various cancers, notably cervical cancer, with types 16 and 18 causing about 70% of cases. With over 600,000 new cervical cancer cases annually as of July 2024, early screening is crucial. Traditional methods are slow, delaying follow-up and treatment.
This kit offers rapid detection of HPV types 16, 18, and 45 DNA in cervical and vulvovaginal swabs, aiding early diagnosis and cancer prevention.¥ 0.00More >
-
SARS-CoV-2
Traditional large testing equipment is often impractical for frequent, quick tests. Quick and accurate testing methods are essential for timely diagnosis and effective management of COVID-19 cases. Accurate COVID-19 diagnosis is crucial due to its global impact and high transmission rates.
This kit provides in vitro qualitative detection of the N gene and ORF1ab gene of SARS-CoV-2 in nasal swabs from suspected COVID-19 cases.¥ 0.00More >
-
Pluslife Secures Indonesian Import License for Groundbreaking Mycobacterium Tuberculosis Nucleic Acid Test Card
Recently, Pluslife's self-developed rapid molecular diagnostic test card for tuberculosis, utilizing tongue swab samples, was awarded an import medical device license by the Indonesian government. This milestone marks a significant breakthrough following the earlier certification of Pluslife’s sputum sample TB diagnostic technology.
2024-09-09
-
MEDICA 2023: Introducing Pluslife's Latest Innovation in Veterinary Diagnostic Technology
Pluslife is currently showcasing its Next-Generation Molecular POCT Solutions at MEDICA, the largest international exhibition for the medical and healthcare sector. Known for its innovative POC molecular diagnostic system, Pluslife invites visitors to witness firsthand how Pluslife's cutting-edge technology is revolutionizing medical and veterinary diagnostics at the forefront of the industry. Join Pluslife at Hall 3, Booth 3K92-11, and meet Pluslife’s CEO Mr. Chong Chen and our team.
2024-08-23
-
Laboratory Evaluation of Pluslife Molecular POCT Solution for Feline Upper Respiratory Infection
The laboratory of Infectious Animal Diseases at the Department of Veterinary Medicine, University of Teramo, recently released a report detailing the findings of a preliminary study. The study aimed to assess the sensitivity and specificity of a Point-of-Care (POC) test for Feline Upper Respiratory Infection (URI). This test relies on identifying nucleic acids from FHV-1, C. felis, and M. felis, utilizing the Pluslife Mini Dock analyzer and Pluslife FCM Card.
2024-08-23
